ProShare Advisors’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $478K | Sell |
16,086
-2,921
| -15% | -$87.3K | ﹤0.01% | 1092 |
|
|
2025
Q4 | $726K | Buy |
19,007
+756
| +4% | +$24.6K | ﹤0.01% | 936 |
|
|
2025
Q3 | $436K | Sell |
18,251
-3,143
| -15% | -$59.1K | ﹤0.01% | 1184 |
|
|
2025
Q2 | $317K | Sell |
21,394
-836
| -4% | -$13.9K | ﹤0.01% | 1404 |
|
|
2025
Q1 | $398K | Sell |
22,230
-3,117
| -12% | -$63.3K | ﹤0.01% | 1219 |
|
|
2024
Q4 | $442K | Buy |
25,347
+6,896
| +37% | +$122K | ﹤0.01% | 1350 |
|
|
2024
Q3 | $258K | Buy |
18,451
+3,994
| +28% | +$41.6K | ﹤0.01% | 1565 |
|
|
2024
Q2 | $119K | Sell |
14,457
-3,964
| -22% | -$26.7K | ﹤0.01% | 1634 |
|
|
2024
Q1 | $142K | Buy |
18,421
+1,557
| +9% | +$13.1K | ﹤0.01% | 1752 |
|
|
2023
Q4 | $152K | Buy |
16,864
+2,497
| +17% | +$18.2K | ﹤0.01% | 1707 |
|
|
2023
Q3 | $128K | Buy |
14,367
+66
| +0.5% | +$931 | ﹤0.01% | 1585 |
|
|
2023
Q2 | $220K | Buy |
14,301
+2,570
| +22% | +$46.7K | ﹤0.01% | 1479 |
|
|
2023
Q1 | $264K | Sell |
11,731
-1,495
| -11% | -$31.8K | ﹤0.01% | 1277 |
|
|
2022
Q4 | $278K | Buy |
13,226
+1,132
| +9% | +$24K | ﹤0.01% | 1285 |
|
|
2022
Q3 | $298K | Buy |
12,094
+306
| +3% | +$7.91K | ﹤0.01% | 1159 |
|
|
2022
Q2 | $285K | Sell |
11,788
-5,844
| -33% | -$147K | ﹤0.01% | 1242 |
|
|
2022
Q1 | $454K | Sell |
17,632
-3,891
| -18% | -$103K | ﹤0.01% | 1339 |
|
|
2021
Q4 | $669K | Buy |
21,523
+1,085
| +5% | +$30.6K | ﹤0.01% | 1270 |
|
|
2021
Q3 | $496K | Sell |
20,438
-5,549
| -21% | -$102K | ﹤0.01% | 1219 |
|
|
2021
Q2 | $379K | Buy |
25,987
+3,231
| +14% | +$63.7K | ﹤0.01% | 1735 |
|
|
2021
Q1 | $568K | Buy |
22,756
+4,038
| +22% | +$112K | ﹤0.01% | 1351 |
|
|
2020
Q4 | $510K | Buy |
18,718
+4,516
| +32% | +$105K | ﹤0.01% | 1267 |
|
|
2020
Q3 | $262K | Buy |
14,202
+1,670
| +13% | +$32.5K | ﹤0.01% | 1273 |
|
|
2020
Q2 | $256K | Buy |
+12,532
| New | +$200K | ﹤0.01% | 1322 |
|
|
2020
Q1 | – | Sell |
-14,903
| Closed | -$212K | – | 1565 |
|
|
2019
Q4 | $212K | Sell |
14,903
-1,443
| -9% | -$18.4K | ﹤0.01% | 1552 |
|
|
2019
Q3 | $189K | Sell |
16,346
-116
| -0.7% | -$1.92K | ﹤0.01% | 1457 |
|
|
2019
Q2 | $331K | Sell |
16,462
-2,094
| -11% | -$41.3K | ﹤0.01% | 1189 |
|
|
2019
Q1 | $420K | Buy |
18,556
+225
| +1% | +$4.97K | ﹤0.01% | 1092 |
|
|
2018
Q4 | $415K | Sell |
18,331
-3,104
| -14% | -$77.2K | ﹤0.01% | 1015 |
|
|
2018
Q3 | $616K | Sell |
21,435
-614
| -3% | -$17.6K | ﹤0.01% | 1020 |
|
|
2018
Q2 | $601K | Sell |
22,049
-1,336
| -6% | -$35.6K | ﹤0.01% | 1033 |
|
|
2018
Q1 | $523K | Sell |
23,385
-3,467
| -13% | -$82.6K | ﹤0.01% | 1078 |
|
|
2017
Q4 | $566K | Buy |
26,852
+2,603
| +11% | +$59.5K | ﹤0.01% | 1070 |
|
|
2017
Q3 | $604K | Buy |
24,249
+1,277
| +6% | +$28.1K | 0.01% | 891 |
|
|
2017
Q2 | $445K | Sell |
22,972
-1,335
| -5% | -$24.2K | ﹤0.01% | 998 |
|
|
2017
Q1 | $449K | Sell |
24,307
-6,438
| -21% | -$126K | ﹤0.01% | 1042 |
|
|
2016
Q4 | $582K | Buy |
30,745
+4,004
| +15% | +$81.9K | 0.01% | 1006 |
|
|
2016
Q3 | $598K | Sell |
26,741
-4,989
| -16% | -$95K | 0.01% | 880 |
|
|
2016
Q2 | $565K | Buy |
31,730
+425
| +1% | +$6.88K | 0.01% | 917 |
|
|
2016
Q1 | $428K | Sell |
31,305
-2,854
| -8% | -$43.3K | 0.01% | 1067 |
|
|
2015
Q4 | $659K | Buy |
34,159
+3,559
| +12% | +$71.1K | 0.01% | 920 |
|
|
2015
Q3 | $620K | Sell |
30,600
-1,745
| -5% | -$51.7K | 0.01% | 859 |
|
|
2015
Q2 | $1.07M | Buy |
32,345
+6,916
| +27% | +$189K | 0.01% | 741 |
|
|
2015
Q1 | $609K | Buy |
25,429
+3,177
| +14% | +$48.4K | 0.01% | 1084 |
|
|
2014
Q4 | $272K | Buy |
+22,252
| New | +$230K | ﹤0.01% | 1579 |
|
|
2014
Q3 | – | Sell |
-10,366
| Closed | -$122K | – | 2357 |
|
|
2014
Q2 | $122K | Buy |
+10,366
| New | +$140K | ﹤0.01% | 2316 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
ProShare Advisors's TVTX Position: Q1 2026 in Review
ProShare Advisors reduced its Travere Therapeutics (TVTX) stake by 15% in Q1 2026, selling an estimated $87.3K and leaving 16,086 shares worth $478K. The position accounts for ﹤0.01% of the portfolio, ranked #1092.
ProShare Advisors first reported a position in TVTX in Q2 2014 and has held it in 46 quarters since. The position peaked at $1.07M in Q2 2015. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- ProShare Advisors held 16,086 shares of Travere Therapeutics worth $478K as of Q1 2026.
- ProShare Advisors sold 2,921 Travere Therapeutics shares in Q1 2026, an estimated $87.3K.
- Travere Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1092 holding.
- ProShare Advisors first reported a position in Travere Therapeutics in Q2 2014 and has held it in 46 quarters since.
- ProShare Advisors's Travere Therapeutics position peaked at $1.07M in Q2 2015.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.